AzTrials
AzTrials

Autism Spectrum DisordersPhase 2STIMAUTNCT04442061

Autism Spectrum Disorders: Double Blind Randomized Placebo-control Active Pilot Study of Transcranial Magnetic Stimulation Applied to the Superior Temporal Sulcus

A Phase 2 study testing Transcranial magnetic stimulation, MRI and Neuronavigation in people with Autism Spectrum Disorders, run by Assistance Publique - Hôpitaux de Paris at 1 site in France.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Difficulties in social interactions are the core feature of autism spectrum disorder (ASD) and are characterized by abnormal social perception, mainly concerning eye gaze. Anatomo-functional abnormalities within the superior temporal sulcus (STS), a key region of the social brain, have been described in ASD. Read more about this study

Who is it for?
Ages 17 to 25 years
Conditions the study is for
Autism Spectrum Disorders
What is being tested?
Transcranial magnetic stimulation, MRI and Neuronavigation
Type of treatment
Medical device
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
20 participants
Where
1 siteFrance
Study dates
2 Feb 2022to 23 Jan 2026
Phase
Phase 2
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 17 to 25 years
  • All sexes
  • No healthy volunteers
  • Child, Adult

Who may be able to join

  • Male or female patient diagnosed with ASD according to DSM-V and ADI-R
  • Patient aged 17 to 25
  • Patient apt to undergo an MRI
  • Patient affiliated with a social security system or beneficiary of such system
  • Informed consent signed by the patient or his legal guardian.

Who cannot join

  • Presence of a somatic pathology
  • Presence of a neurological pathology
  • Presence of epilepsy, history of seizure.
  • Initiation, discontinuation or modification of neuroleptics or benzodiazepines treatment in the previous month
  • Contraindication to MRI (pacemaker, intracorporeal metallic foreign body, metal worker)
  • Contraindication to the use of TMS (epilepsy and family epilepsy, presence of craniotomy scar, pacemaker or pacemaker, intraocular or intracerebral metallic foreign body, cochlear implant, cardiac valve or metallic surgical arterial material, metallic material capable of concentrating radio frequency pulses)
  • Pregnancy and breast-feeding
  • Participation in another pilot study or clinical trial that does not allow participation in this protocol.

Trial locations and contacts

1 site in 1 country.

France1 site
  • Hôpital Necker Enfants Malades - Service de radiologie pédiatrique

    Paris, 75015

Other trials in France

About this study

Difficulties in social interactions are the core feature of autism spectrum disorder (ASD) and are characterized by abnormal social perception, mainly concerning eye gaze. Anatomo-functional abnormalities within the superior temporal sulcus (STS), a key region of the social brain, have been described in ASD. The investigators had recently shown that it is possible to modulate the neural activity of the STS with transcranial magnetic stimulation (TMS) with an impact on social perception, measured by eye-tracking. In the context of ASD, stimulation of the STS with excitatory TMS could lead to an improvement in social perception, which would open up new therapeutic strategies. The purpose of this double-blind, randomized, placebo-controlled study is to apply a therapeutic TMS protocol (10 daily sessions) at the right STS in young adults with ASD to improve their social behavior, objectively measured using eye-tracking.

Read the detailed description

Autism Spectrum Disorders (ASD) are neuro-developmental disorders presumably related to neural circuit alterations. The symptoms, that start very early in development and persist through adulthood, can lead to severe handicap. Even though a wide variety of clinical severity exists, difficulties in social interactions are a core feature of ASD. These difficulties are characterized by social perception abnormalities, manifested mainly through abnormal eye contact. Such abnormalities have been largely confirmed in the last decade by eye-tracking studies, which allow objective and quantitative investigation of gaze behaviour. Studies with adults and children with ASD during visualization of social scene have shown a lack of preference for socially relevant information, mainly faces and eyes.

In the typically developing brain, socially relevant information is processed within a specific network, called the social brain. Functional MRI (fMRI) activation studies have shown the implication of a key region of the social brain, namely the superior temporal sulcus (STS), is in processing social information, ranging from the perception of eyes, faces and voices to the more complex processes of social cognition. Over the last decades, brain imaging studies investigating the neuro basis of ASD have consistently described anatomical and functional abnormalities within the social brain, particularly within the STS Currently there are important limitations in the therapeutic interventions available for ASD. Pharmacological treatments are only indicated for psychiatric comorbidity and has no impact on ASD core manifestations. Behavioural interventions, on the other hand, are generally expensive, time-consuming and have modest results. In more recent years non-invasive neuromodulation techniques, such as Transcranial Magnetic Stimulation (TMS), have raised hope as effective tool to address ASD core manifestations. Indeed, modulating the neural activity of STS with an impact on social perception opens new therapeutic perspectives in ASD. The effect of TMS on social behaviour has been recently showed by a study from our lab. Following an inhibition of the right STS by inhibitory TMS, healthy volunteers look less at the eyes of the characters during the visualization of social scenes.

In this context, the main objective of this study is to investigate the effect of repetitive session of TMS applied to the STS on social perception in patients with ASD. In addition, the investigators aim to research the impact of putative changes in social perception in broader social behaviour using clinical scales. Finally, the investigators aim to research putative changes in brain functioning at rest by measuring rest cerebral blood flow using Arterial Spin Labeling (ASL)-MRI before and after TMS. This is a double-blind, randomized, placebo-controlled therapeutic trial, ultimately aiming to improve broader social behaviour.

For that purpose, the investigators will include in the present study 20 participants with non-syndromic ASD aged from 18 to 25 years old. Social perception will be measured using an eye-tracking during passive visualization of social stimuli. All patients will undergo an MRI for neuronavigation purposes and to obtain rest cerebral blood flow measures using arterial spin labelling MRI sequence, as well as clinical scales to evaluate their global social behavior: clinical global impressions (CGI), "évaluation des comportements autistiques revise" (ECA-R) and autism behavior checklist (ABC). The 20 patients will be automatically randomized in the active TMS arm (n = 10), or in the placebo arm (n = 10). Patients will undergo 10 sessions of TMS applied to the posterior part of the right superior STS, from Monday to Friday for two consecutive weeks. Following the 10 sessions, evaluations will be performed: 5 days, 1 month and 3 months after the end of the treatment.

The investigators expect that stimulation of the posterior part of the STS, a region shown to be strongly implicated in processing social information, mainly from the eyes, would lead to an increase in eye-gaze perception and thus promote access to social cues necessary for adapted broader social behavior. If so, TMS could be further considered as an alternative therapeutical intervention in ASD.

Being tested
Transcranial magnetic stimulation, MRI, Neuronavigation, Eye-tracking, Salivary samples
Keywords
transcranial magnetic stimulation, superior temporal sulcus
Medical subject headings
Autism Spectrum Disorder

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Transcranial magnetic stimulationDevice

    Before the stimulation, identification of a motor "hotspot" and active motor threshold (AMT) will be performed. The TMS will be applied on the intermittent theta-burst modality (iTBS), i. e., 2 s of TBS trains (30 pulses) repeated every 10 s for 190 s, with a total number of 600 pulses (Huang et al, 2005). The whole TMS session, including preparation, will last up to 1h.

    The sham TMS follows the same procedure of the active TMS without stimulating cortical tissue

  • MRIDevice

    Anatomical and functional images will be acquired and review by an experienced neuro-radiologist.

  • NeuronavigationDevice

    The neuronavigation system will allow to guide the stimulation using the individual anatomical MRI acquired with MRI, and to record the position and orientation of the coil during successive stimulations

  • Eye-trackingDevice

    Eye movements and follow a person's gaze will be recorded during visualization of stimuli presented in the screen by analyzing images of the eye captured by an infrared camera

  • Salivary samplesGenetic

    The DNA will be extracted from the salivary sample to genotyping analyses on the BDNF (Val66Met) and COMT (Val158Met) polymorphism

  • Clinical scalesOther

    CGI, E-CAR and ABC will be used for behavior and clinical evaluation

Study groups in NCT04442061
Study groupRoleWhat they receive
Active transcranial magnetic stimulationActive comparatorexcitatory TMS will be applied to the right posterior STS
Receives: Device: Transcranial magnetic stimulation; Device: MRI; Device: Neuronavigation; Device: Eye-tracking; Genetic: Salivary samples; Other: Clinical scales
Sham transcranial magnetic stimulationSham comparatorThe sham TMS follows the same procedure of the active TMS without stimulating cortical tissue
Receives: Device: Transcranial magnetic stimulation; Device: MRI; Device: Neuronavigation; Device: Eye-tracking; Genetic: Salivary samples; Other: Clinical scales

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Changes gaze pattern to the eyes

    Changes number of fixations to the eyes measured by eye-tracking during passive visualization of social scenes following the 10 iTBS sessions applied to the right pSTS compared to baseline measures.

    Measured: Until 3 months after iTBS sessions

Secondary outcomes (20)
  1. Autistic Behavior Checklist (ABC) scale at v1

    Evaluate social behavior and autistic symptoms (Lower score = 0 Higher score mean worse outcome = 174)

    Measured: 5 days before iTBS sessions

  2. Autistic Behavior Checklist (ABC) scale at v2

    Evaluate social behavior and autistic symptoms (Lower score = 0 Higher score mean worse outcome = 174)

    Measured: 5 days after iTBS sessions

  3. Autistic Behavior Checklist (ABC) scale at v3

    Evaluate social behavior and autistic symptoms (Lower score = 0 Higher score mean worse outcome = 174)

    Measured: 1 month after iTBS sessions

  4. Autistic Behavior Checklist (ABC) scale at v4

    Evaluate social behavior and autistic symptoms (Lower score = 0 Higher score mean worse outcome = 174)

    Measured: 3 months after iTBS sessions

  5. "Evaluation des comportements Autistiques révisée" (ECA-R) scale at v1

    Evaluate social behavior and autistic symptoms (Lower score = 0 Higher score mean worse outcome = 116)

    Measured: 5 days before iTBS sessions

  6. "Evaluation des comportements Autistiques révisée"(ECA-R) scale at v2

    Evaluate social behavior and autistic symptoms (Lower score = 0 Higher score mean worse outcome = 116)

    Measured: 5 days after iTBS sessions

  7. "Evaluation des comportements Autistiques révisée" (ECA-R) scale at v3

    Evaluate social behavior and autistic symptoms (Lower score = 0 Higher score mean worse outcome = 116)

    Measured: 1 month after iTBS sessions

  8. "Evaluation des comportements Autistiques révisée" (ECA-R) scale at v4

    Evaluate social behavior and autistic symptoms (Lower score = 0 Higher score mean worse outcome = 116)

    Measured: 3 months after iTBS sessions

  9. Clinical Global Impression (CGI) scale at v1

    global functioning (Lower score = 1 Higher score mean worse outcome=16)

    Measured: 5 days before iTBS sessions

  10. Clinical Global Impression (CGI) scale at v2

    global functioning (Lower score = 1 Higher score mean worse outcome=16)

    Measured: 5 days after iTBS sessions

  11. Clinical Global Impression (CGI) scale at v3

    global functioning (Lower score = 1 Higher score mean worse outcome=16)

    Measured: 1 month after iTBS sessions

  12. Clinical Global Impression (CGI) scale at v4

    global functioning (Lower score = 1 Higher score mean worse outcome=16)

    Measured: 3 months after iTBS sessions

  13. Changes in rest brain fonctionning at v1

    by measuring whole brain cerebral blood flow at rest using MRI-ASL

    Measured: 5 days before iTBS sessions

  14. Changes in rest brain fonctioning at v2

    by measuring whole brain cerebral blood flow at rest using MRI-ASL

    Measured: 5 days after iTBS sessions

  15. Changes in rest brain fonctioning at v4

    by measuring whole brain cerebral blood flow at rest using MRI-ASL

    Measured: 3 months after iTBS sessions

  16. Putative changes on brain functional connectivity at rest at V1

    by using the resting state sequence using MRI-ASL

    Measured: 5 days before iTBS sessions

  17. Putative changes on brain functional connectivity at rest at V2

    by using the resting state sequence using MRI-ASL

    Measured: 5 days after iTBS sessions

  18. Putative changes on brain functional connectivity at V4

    by using the resting state sequence using MRI-ASL

    Measured: 3 months after iTBS sessions

  19. Anatomical connectivity abnormalities

    by using the diffusion tensor imaging sequence (DTI) using MRI-ASL

    Measured: At V1 : 5 days before iTBS sessions

  20. BDNF/COMT polymorphisms

    Research of BDNF/COMT polymorphisms on salivary samples

    Measured: 5 days after baseline

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted22 Jun 2020
  2. Study start2 Feb 2022
  3. Primary completion22 Jan 2026
  4. Study completion23 Jan 2026

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Triple blind
Who is masked
Participant, Investigator, Outcomes assessor
Enrolment
20 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04442061
Sponsor's protocol ID
APHP191009
Acronym
STIMAUT
Status last verified
Apr 2026
First submitted
20 Apr 2020
Last updated
1 May 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing Transcranial magnetic stimulation, MRI and Neuronavigation in people with Autism Spectrum Disorders, run by Assistance Publique - Hôpitaux de Paris at 1 site in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 1 May 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Changes gaze pattern to the eyes (time frame: Until 3 months after iTBS sessions). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 May 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in